<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03297125</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00000087</org_study_id>
    <nct_id>NCT03297125</nct_id>
  </id_info>
  <brief_title>Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI</brief_title>
  <official_title>Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective, nonrandomized controlled phase IV study is to compare&#xD;
      standard and advanced MRI for their ability to predict response to Optune therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol Summary: Optune therapy is a newly approved treatment for patients with&#xD;
      glioblastoma. This therapy demonstrated comparable outcomes for patients with recurrent GBM,&#xD;
      in comparison to standard therapies, but better quality of life. More recently, in an interim&#xD;
      analysis of 315 patients with GBM, adding Tumor Treating Fields (TTFields) to maintenance&#xD;
      temozolomide chemotherapy significantly prolonged progression-free and overall survival. It&#xD;
      also has demonstrated promise in other cancers such as pancreas, mesothelioma, ovarian and&#xD;
      lung. However, in order to optimize the treatment regimen, and potentially predict which&#xD;
      patients are most likely to respond, reliable ways of evaluation are necessary. Advanced&#xD;
      perfusion and diffusion MRI methods have shown utility with other treatments such as&#xD;
      bevacizumab. Preliminary data suggests the same might be true for the evaluation of Optune&#xD;
      therapy. The team therefore proposes to determine the utility of these methods to predict&#xD;
      response to Optune therapy. A successful result will have wide-ranging implications not only&#xD;
      for the optimization of Optune treatment of brain cancer but also other cancers shown to&#xD;
      benefit from this novel therapy.&#xD;
&#xD;
      Objective: To compare standard and advanced MRI for their ability to predict response to&#xD;
      Optune therapy. The team's approach will be to obtain both standard and advanced MRI in&#xD;
      patients with newly diagnosed glioblastoma undergoing adjuvant chemotherapy plus Optune&#xD;
      therapy. The ability of standard and advanced MRI to predict response will be assessed. The&#xD;
      hypothesis is that perfusion and/or diffusion imaging metrics can be used to predict response&#xD;
      to and elucidate mechanisms of action for Optune treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival.</measure>
    <time_frame>Six months.</time_frame>
    <description>The number of subjects alive at six months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival.</measure>
    <time_frame>One year.</time_frame>
    <description>The number of subjects alive at one year.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Eligible Subjects</arm_group_label>
    <description>All enrolled subjects undergoing Optune therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>Standard MRI.</description>
    <arm_group_label>Eligible Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Advanced MRI.</intervention_name>
    <description>Perfusion and diffusion MRI.</description>
    <arm_group_label>Eligible Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with newly diagnosed or recurrent glioblastoma who have self-selected Optune&#xD;
        therapy (group 1) or declined Optune therapy (group 2).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed glioblastoma (GBM), World Health Organization (WHO) grade IV.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Optune compliance &lt; 75%; they would be excluded from the final analyses.&#xD;
&#xD;
          -  History of craniectomy or significant skull defect (contraindication to Optune).&#xD;
&#xD;
          -  Active implantable medical device (e.g., deep brain stimulator (DBS), spinal cord&#xD;
             stimulator, pacemaker, defibrillator, vagus nerve stimulator, programmable shunt).&#xD;
&#xD;
          -  Karnofsky Performance Status (KPS) &lt; 60.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Connelly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cathy Marszalkowski</last_name>
    <phone>414-955-1183</phone>
    <email>cmars@mcw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Froedtert Hospital &amp; Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Connelly, MD</last_name>
      <phone>414-805-5200</phone>
      <email>JConnelly@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 26, 2017</study_first_submitted>
  <study_first_submitted_qc>September 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2017</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Jennifer Connelly, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Optune Therapy</keyword>
  <keyword>MRI</keyword>
  <keyword>NovoCure-TTF-200A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

